Urokinase-type plasminogen activator and its inhibitor plasminogen activator inhibitor-1: New functional risk factors in head and neck squamous cell cancer

Oncology Reports

Volumn 4, Issue 4, 1997, Pages 853-855

  Wollenberg, B ^a,b   Jan, N V ^a   Jund, R ^a   Chaubal, S ^a   Untch, M ^a  

^a UNIVERSITY OF MUNICH   (Germany)

^b LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

Head and neck squamous cell cancer; Plasminogen activator inhibitor 1 (PAI 1); Plasminogen activators; Tumor associated proteolysis; Urokinase; Urokinase type plasminogen activator (u PA)

Indexed keywords

COLLAGEN; LAMININ; PLASMINOGEN ACTIVATOR INHIBITOR; UROKINASE;

ADULT; AGED; ARTICLE; BASEMENT MEMBRANE; CANCER INVASION; CLINICAL ARTICLE; ENZYME LINKED IMMUNOSORBENT ASSAY; EXTRACELLULAR MATRIX; FEMALE; HEAD AND NECK CANCER; HUMAN; MALE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN DEGRADATION; REGRESSION ANALYSIS; RISK FACTOR; SQUAMOUS CELL CARCINOMA; TUMOR BIOPSY;

EID: 0030744040     PISSN: 1021335X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Tryggvason K, Hoyhthya M and Salo T: Proteolytic degradation of extracellular matrix in tumor invasion. Biochem Biophys Acta 97: 191-217, 1988.
2. Blasi F: Urokinase and urokinase receptor: a paracrine/ autocrine system regulating cell migration and invasiveness. Bioessay 15: 105-111, 1993.
3. Heiss MM, Babic R and Allgayer H: Tumor-associated proteolysis and prognosis: new functional risk factors in gastric cancer defined by the urokinase-type plasminogen activator system. J Clin Oncol 13: 2084-2093, 1995.
4. Ossowski L, Clunie G and Masucci M T: In vivo paracrine interaction between urokinase and its receptor: effect on tumor cell invasion. J Cell Biol 115: 1107-1112, 1991.
5. Mourik JA, Lawrence DA and Loskutoff DJ: Purification of an inhibitor of plasminogen activator (antiactivator) sythesized by endothelial cells. J Biol Chem 259: 14914-14921, 1984.
6. Gelehrter TD, Barouski-Miller PA, Coleman PL and Cwikel BJ: Hormonal regulation of plasminogen activator in rat hepatoma cells. Mol Cell Biochem 53/54: 11-21, 1983.
7. Wiman B, Chmielweska J and Ranby M: Inactivation of tissue plasminogen activator in plasma. Demonstration of a complex with a new rapid inhibitor. J Biol Chem 259: 3644-3647, 1984.
8. Erickson LA, Hekman CM and Loskutoff DJ: The primary plasminogen activator inhibitors in endothelial cells, platelets, serum, and plasma are immunologically related. Proc Natl Acad Sci USA 82: 8710-8714, 1985.
9. Grondahl-Hansen J, Christensen IJ, Rosenquist C, Brünner N, Mouridsen HT, Dano K and Blichert-Toft M: High levels of urokinase-type plasminogen activators and its inhibitor PAI-1 in cytosolic extracts of breast carcinomas are associated with poor prognosis. Cancer Res 53: 2513-2521, 1993.
10. Jänicke F, Schmitt M, Hafter R, Hollrieder A, Babic R, Ulm K, Gössner W and Graeff H: Urokinase-type plasminogen activator (u-PA) antigen is a predictor of early relapse in breast cancer. Fibrinolysis 4: 69-78, 1990.
11. Pedersen H, Grondahl J, Francis D, Osterlind K, Hansen HH, Dano K and Brünner N: Urokinase and plasminogen activator inhibitor type 1 in pulmonary adenocarcinoma. Cancer Res 54: 120-122, 1994.
12. Ganesh S, Sier CFM, Griffioen G, Vloedgraven HJM, Boer A, Welvart K, van de Velde C, van Krieken HJM, Verheijen JH, Lamers CBH and Verspaget HW: Prognositic relevance of plasminogen activators and their inhibitors in colorectal cancer. Cancer Res 54: 4065-4071, 1994.
13. Tanaka N, Fukao H and Ueshima S: Plasminogen activator inhibitor 1 in human carcinoma tissues. Int J Cancer 48: 20-27, 1991.
14. Bianchi E, Cohen RL and Thor AT: The urokinase receptor is expressed in invasive breast cancer but not in normal breast tissue. Cancer Res 54: 861-866, 1994.
15. Jankun J, Merrick HW and Goldblatt PJ: Expression and localization elements of the plasminogen activation system in benign breast disease and breast cancer. J Cell Biol 53: 135-144, 1993.
16. Duffy MJ, Reilly D and O'Sullivan C: Urokinase-plasminogen activator, a new and independent prognostic marker in breast cancer. Cancer Res 50: 6827-6829, 1990.
17. Mulcahy HE, Duffy MJ and Gibbons D: Urokinase-type plasminogen activator and outcome in Dukes' B colorectal cancer. Lancet 344: 583-584, 1994.
18. Sappino AP, Busso NB, Belin D and Vassalli JD: Increase of urokinase-type plasminogen activator gene expression in human lung and breast carcinoma. Cancer Res 47: 4043-4046, 1987.
19. Clayman G, Wang SW, Nicholson GL, El-Naggar A, Mazar A, Henkin J and Blasi F: Regulation of urokinase-type plasminogen activator expression in squamous cell carcinoma of the oral cavity. Int J Cancer 54: 73-80, 1993.
20. Sappino AP, Pelin D, Huarte J, Hirschel-Scholz S, Saurat JH and Vassalli JD: Differential protease expression by cutaneous squamous and basal cell carcinomas. J Clin Invest 88: 1073-1079, 1991.
21. Robbins KC, Summaria L, Hsieh B and Shah R: The peptide chains of human plasmin. J Biol Chem 242: 2333-2342, 1967.
22. Salo T, Liotta L, Keski-Oja J, Turpeenniemi-Hujanen T and Tryggvason K: Secretion of basement collagen degrading enzyme and plasminogen activator by transformed cells - role in metastasis. Int J Cancer 30: 669-673, 1982.
23. Ossowski L and Reich E: Antibodies to plasminogen activator inhibit human tumor metastasis. Cell 35: 2759-2771, 1983.